BD posts healthy global, U.S. Q4 revenues

By The Science Advisory Board staff writers

November 5, 2020 -- Becton Dickinson (BD) has reported worldwide fourth quarter revenues of $4.8 billion (end-September 30), up 4.4% compared to the same period in 2019. U.S. revenues increased 7.4%, to $2.7 billion.

The company's COVID-19 testing sales totaled more than $440 million for the quarter, it said.

Its Life Sciences segment posted revenues of $1.5 billion, up 31.2% compared to the same period last year. However, the company's Medical segment posted worldwide revenues of $2.3 billion, down 4.9% from 2019, and its Interventional segment revenues decreased 3.4% compared to 2019, at $978 million, which BD attributed in part to the impact of COVID-19.


Copyright © 2020 scienceboard.net
 


Email Address:

First Name:

Last Name:

Learn about ScienceBoard

Get the latest life sciences research and industry news, delivered straight to your inbox, for free.

Why subscribe?

ScienceBoard is uniquely focused on the business of research, addressing the biggest problems that the biomedical industry face. You’ll get breaking news, events coverage, and deep dives into the science that drives innovation, delivered to your inbox daily.

I have read and agree to the privacy policy and terms of service and wish to opt-in for ScienceBoard.net.